<DOC>
	<DOC>NCT02699385</DOC>
	<brief_summary>The purpose of this study is to demonstrate that domperidone suspension plus oral rehydration therapy (ORT) is more effective than placebo plus ORT at reducing the symptoms of vomiting associated with acute gastroenteritis (AG) within the first 48 hours of treatment administration in pediatric participants with AG and mild-to-moderate dehydration.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis</brief_title>
	<detailed_description>This is a randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), parallel-group, placebo-controlled, multicenter (when more than one hospital or medical school team work on a medical research study) study. The study consists of 3 Phases: Screening Phase (-2 to 0 hours prior to baseline on Day 1), Double-blind treatment Phase (up to 7 Days) and follow-up Phase (7 Days). The duration of participation in the study for each participant is at most 15 Days. Efficacy and safety of domperidone will be evaluated. Participants' safety will be monitored throughout the study.</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Domperidone</mesh_term>
	<criteria>The participant presents with at least 3 episodes of nonbilious, nonbloody vomiting within the 24 hours prior to visiting the physician's office. The participant has at least 2 signs and symptoms other than vomiting consistent with acute gastroenteritis (AG) (example, fever, nausea, diarrhea, abdominal pain, bloating, or discomfort) within 3 hours prior to visiting the physician's office The participant has mildtomoderate dehydration The participant had at least 1 episode of nonbloody diarrhea within the 24 hours prior to the visiting the physician's office The participant has severe dehydration or severe malnutrition The participant who has vomiting and clinical symptoms for longer than 72 hours prior to the baseline physician's office visit The participant needs intravenous (IV) fluid replacement The participant has chronic severe diarrhea, a previous history of Helicobacter pylori infection or received treatment for H. pyloriinduced gastritis, active peptic ulcer, celiac disease, Crohn's disease, ulcerative colitis, eosinophilic esophagitis, malabsorption, short bowel syndrome, postviral gastroparesis, cyclic vomiting syndrome, or previous gastrointestinal surgery The participant has upper respiratory symptoms such as cough, congestion, otitis media or pharyngitis</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastroenteritis</keyword>
	<keyword>Domperidone</keyword>
	<keyword>Pediatric participants</keyword>
</DOC>